CDKN2A and neoplasm: Over half of HCC cases exhibit somatic tumor inactivation of cyclin-dependent kinase inhibitor 2A (CDKN2A), the gene that encodes p16INK4A and p14ARF proteins, owing to epigenetic silencing, loss-of-function mutations or chromosomal deletion (The Cancer Genome Atlas Research Network, 2017).